What can governmental agencies do to lower the risk of cell therapies and the enterprises commercializing them?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Giebel, L. Stem cells—a hard sell to investors. Nat. Biotechnol. 23, 798–800 (2005).
Alliance for Regenerative Medicine. 2014 Regenerative Medicine Annual Industry Report (2014).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schachter, B. Therapies of the state. Nat Biotechnol 32, 736–741 (2014). https://doi.org/10.1038/nbt.2984
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2984
This article is cited by
-
UK catapults precision medicine
Nature Biotechnology (2015)